JP2012526096A - Gpr119調節因子 - Google Patents
Gpr119調節因子 Download PDFInfo
- Publication number
- JP2012526096A JP2012526096A JP2012509115A JP2012509115A JP2012526096A JP 2012526096 A JP2012526096 A JP 2012526096A JP 2012509115 A JP2012509115 A JP 2012509115A JP 2012509115 A JP2012509115 A JP 2012509115A JP 2012526096 A JP2012526096 A JP 2012526096A
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- mixture
- carboxylate
- dihydro
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(CC1)C(*)CN1I Chemical compound CC(CC1)C(*)CN1I 0.000 description 5
- ZFFYPGZDXUPKNK-UHFFFAOYSA-N C1c2cccnc2NC1 Chemical compound C1c2cccnc2NC1 ZFFYPGZDXUPKNK-UHFFFAOYSA-N 0.000 description 1
- CGFDGOYXOHRVNJ-UHFFFAOYSA-N CC(C)OC(N(C1)CC2[IH]OCC1C2OC1=NCNC(N(CCc2c3)c2ccc3S(C)(=O)=O)=C1C#N)=O Chemical compound CC(C)OC(N(C1)CC2[IH]OCC1C2OC1=NCNC(N(CCc2c3)c2ccc3S(C)(=O)=O)=C1C#N)=O CGFDGOYXOHRVNJ-UHFFFAOYSA-N 0.000 description 1
- UXFHKDPLMDJQBU-UHFFFAOYSA-N CC(C)OC(N(C1)CC2[IH]OCC1C2Oc(ncnc1N(CC2)c(cc3)c2cc3S(C)(=O)=O)c1C#N)=O Chemical compound CC(C)OC(N(C1)CC2[IH]OCC1C2Oc(ncnc1N(CC2)c(cc3)c2cc3S(C)(=O)=O)c1C#N)=O UXFHKDPLMDJQBU-UHFFFAOYSA-N 0.000 description 1
- BJCYQOJAGUALBP-UHFFFAOYSA-N CC(C)OC(N(CC1)CCC1Oc1ncnc(N2c3cccnc3CC2)c1)=O Chemical compound CC(C)OC(N(CC1)CCC1Oc1ncnc(N2c3cccnc3CC2)c1)=O BJCYQOJAGUALBP-UHFFFAOYSA-N 0.000 description 1
- AHMZSSLCWNLSNV-UHFFFAOYSA-N CCC1(CC1)OC(N(C1)CC2[IH]OCC1C2Oc1c(C)c(N(CC2)c3c2nccc3)ncn1)=O Chemical compound CCC1(CC1)OC(N(C1)CC2[IH]OCC1C2Oc1c(C)c(N(CC2)c3c2nccc3)ncn1)=O AHMZSSLCWNLSNV-UHFFFAOYSA-N 0.000 description 1
- RWQXGPXKJSGPLO-UHFFFAOYSA-N CSc(cc1CC2)ccc1N2c1cc(Cl)ncn1 Chemical compound CSc(cc1CC2)ccc1N2c1cc(Cl)ncn1 RWQXGPXKJSGPLO-UHFFFAOYSA-N 0.000 description 1
- MBSVWPQYOQSDJS-JYPKXMCJSA-N C[C@@H](CC(C1)C2(C)C)C2(CS(O)(=O)=O)C1=O Chemical compound C[C@@H](CC(C1)C2(C)C)C2(CS(O)(=O)=O)C1=O MBSVWPQYOQSDJS-JYPKXMCJSA-N 0.000 description 1
- SHAPDKYVJFGHSO-GXTWGEPZSA-N Cc(c(N(C1)Cc2c1cn[n]2C)ncn1)c1O[C@H](CCNC1)[C@H]1F Chemical compound Cc(c(N(C1)Cc2c1cn[n]2C)ncn1)c1O[C@H](CCNC1)[C@H]1F SHAPDKYVJFGHSO-GXTWGEPZSA-N 0.000 description 1
- OSSKDIIHMMALEV-UHFFFAOYSA-N OC(c(cc1CC2)ccc1N2c1ncnc(Cl)c1)=O Chemical compound OC(c(cc1CC2)ccc1N2c1ncnc(Cl)c1)=O OSSKDIIHMMALEV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17652809P | 2009-05-08 | 2009-05-08 | |
| US61/176,528 | 2009-05-08 | ||
| US32046210P | 2010-04-02 | 2010-04-02 | |
| US61/320,462 | 2010-04-02 | ||
| PCT/IB2010/051567 WO2010128414A1 (en) | 2009-05-08 | 2010-04-12 | Gpr 119 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526096A true JP2012526096A (ja) | 2012-10-25 |
| JP2012526096A5 JP2012526096A5 (cg-RX-API-DMAC7.html) | 2013-05-16 |
Family
ID=42799729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012509115A Withdrawn JP2012526096A (ja) | 2009-05-08 | 2010-04-12 | Gpr119調節因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120052130A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2427448A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012526096A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2759891A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010128414A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530758A (ja) * | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5657518B2 (ja) * | 2009-02-18 | 2015-01-21 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US8293729B2 (en) | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ |
| ES2557895T3 (es) | 2010-03-19 | 2016-01-29 | Pfizer Inc | Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina |
| WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
| CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| US9000175B2 (en) | 2010-11-26 | 2015-04-07 | Lupin Limited | Bicyclic GPR119 modulators |
| EA022375B1 (ru) | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| JP2014520879A (ja) | 2011-07-15 | 2014-08-25 | ファイザー・インク | Gpr119調節因子 |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| AU2012335220B2 (en) | 2011-11-11 | 2017-06-01 | Pfizer Inc. | 2-thiopyrimidinones |
| AU2013245353A1 (en) | 2012-04-06 | 2014-09-25 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物 |
| CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014125394A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2813505A1 (en) | 2013-06-14 | 2014-12-17 | Asceneuron SA | Tetraaza-cyclopenta[a]indenyl derivatives |
| ES2665153T3 (es) | 2013-10-09 | 2018-04-24 | Pfizer Inc. | Antagonistas del receptor EP3 de prostaglandina |
| CU24395B1 (es) | 2014-03-17 | 2019-04-04 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| PL3536685T3 (pl) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4 |
| JP6111002B1 (ja) | 2014-04-10 | 2017-04-05 | ファイザー・インク | 2−アミノ−6−メチル−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル−1,3−チアゾール−4−イルアミド |
| WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| SG11201708407TA (en) | 2015-05-05 | 2017-11-29 | Pfizer | 2-thiopyrimidinones |
| WO2016193844A1 (en) | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| DK3310784T3 (da) | 2015-06-17 | 2020-11-09 | Pfizer | Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| US20180230127A1 (en) | 2015-08-13 | 2018-08-16 | Pfizer Inc. | Bicyclic-Fused Heteroaryl Or Aryl Compounds |
| HRP20210472T1 (hr) | 2015-08-27 | 2021-05-14 | Pfizer Inc. | Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4 |
| WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | N−[2−(2−アミノ−6,6−二置換−4,4a,5,6−テトラヒドロピラノ[3,4−d][1,3]チアジン−8a(8H)−イル)−1,3−チアゾール−4−イル]アミド |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| EP3353174A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors |
| TN2018000198A1 (en) | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| US10906888B2 (en) | 2016-07-14 | 2021-02-02 | Pfizer Inc. | Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| JP7161605B2 (ja) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Nash/nafldおよび関連疾患の治療のための組合せ |
| WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| JP7498199B2 (ja) | 2019-06-28 | 2024-06-11 | ファイザー・インク | 種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体 |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| LT4161927T (lt) | 2020-06-09 | 2024-09-25 | Pfizer Inc. | Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
| IL312296A (en) | 2021-12-01 | 2024-06-01 | Pfizer | 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART |
| WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| AU2023358062A1 (en) | 2022-10-07 | 2025-03-20 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
| IL319392A (en) | 2022-10-18 | 2025-05-01 | Pfizer | Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| WO2024127297A1 (en) | 2022-12-16 | 2024-06-20 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
| CN121311466A (zh) | 2023-04-14 | 2026-01-09 | 辉瑞大药厂 | 葡萄糖依赖性促胰岛素多肽受体拮抗剂及其用途 |
| WO2025099566A1 (en) | 2023-11-08 | 2025-05-15 | Pfizer Inc. | A crystalline form of 6-fluoro-3-(2,4,5-trifluoro-3-methoxyphenyl)-1-benzothiophene-2-carboxylic acid |
| TW202539633A (zh) | 2024-02-01 | 2025-10-16 | 美商輝瑞股份有限公司 | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 |
| WO2025224599A1 (en) | 2024-04-22 | 2025-10-30 | Pfizer Inc. | Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026013531A1 (en) | 2024-07-10 | 2026-01-15 | Pfizer Inc. | Spiro[2.5]octane compounds |
| WO2026033382A1 (en) | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| WO2026042018A1 (en) | 2024-08-21 | 2026-02-26 | Pfizer Inc. | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes |
| WO2026078617A1 (en) | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078671A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078673A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078674A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078672A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078670A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026088071A1 (en) | 2024-10-23 | 2026-04-30 | Pfizer Inc. | Substituted fused heteroaryl lactam compounds |
| WO2026154417A1 (en) | 2025-01-17 | 2026-07-23 | Pfizer Inc. | Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602008002733D1 (de) * | 2007-03-08 | 2010-11-04 | Irm Llc | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität |
| EP2152707B1 (en) * | 2007-05-04 | 2012-06-20 | Bristol-Myers Squibb Company | [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
| KR101536021B1 (ko) * | 2007-10-16 | 2015-07-10 | 다이이찌 산쿄 가부시키가이샤 | 피리미딜 인돌린 화합물 |
| AR076024A1 (es) * | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
-
2010
- 2010-04-12 EP EP10717259A patent/EP2427448A1/en not_active Withdrawn
- 2010-04-12 WO PCT/IB2010/051567 patent/WO2010128414A1/en not_active Ceased
- 2010-04-12 CA CA2759891A patent/CA2759891A1/en not_active Abandoned
- 2010-04-12 JP JP2012509115A patent/JP2012526096A/ja not_active Withdrawn
- 2010-04-12 US US13/318,152 patent/US20120052130A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530758A (ja) * | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2427448A1 (en) | 2012-03-14 |
| WO2010128414A1 (en) | 2010-11-11 |
| CA2759891A1 (en) | 2010-11-11 |
| US20120052130A1 (en) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526097A (ja) | Gpr119調節因子 | |
| US20120052130A1 (en) | Gpr 119 modulators | |
| US20100285145A1 (en) | Gpr 119 modulators | |
| KR102172742B1 (ko) | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 | |
| TWI433843B (zh) | Gpr119調節子 | |
| JP2012528847A (ja) | Gpr119調節因子としてのl−(ピペリジン−4−イル)−ピラゾール誘導体 | |
| WO2010106457A2 (en) | 3-oxa-7-azabicyclo[3.3.1]nonanes | |
| JP2013511571A (ja) | Gpr119阻害剤としてのイミダゾ−ピラゾール | |
| JP2018527337A (ja) | 二環式縮合ヘテロアリールまたはアリール化合物 | |
| WO2013011402A1 (en) | Gpr 119 modulators | |
| JP2013505290A (ja) | Gpr119調節因子 | |
| EP3028703B1 (en) | Piperidine derivatives as wnt signaling inhibitor | |
| OA16400A (en) | 4-(5-cyano-pyrazol-1-yl)-piperidine derivatives as GPR 119 modulators. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130401 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130401 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20140328 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140410 |